Emplicure signs development agreement with Uppsala university regarding biological medicinesAs part of broadening Emplicure's project and product development, an agreement has been signed with the Department of Materials Science at Uppsala University, Sweden.
The agreement includes advanced materials science characterization of drug formulations developed by Emplicure, as well as collaboration to develop new formulations of biological drugs (biologics). Medicines have traditionally been manufactured by chemical means, but in recent decades more and more medicines have been manufactured through biological processes. Thanks to this development, there are now new effective treatments for several serious and chronic diseases, such as rheumatism and cancer.
"Using our patented bioceramic platforms with new biological substances and thereby developing innovative biological drugs with specific release profiles will contribute to new and completely unique treatment options for patients. We see great potential in being able to use our bioceramic platforms in biological drugs, with increased patient benefit and more efficient treatment as a result" says CEO Torbjörn W. Larsson, CEO of Emplicure. Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: [email protected]
Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: [email protected]
Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]
The following documents can be retrieved from beQuoted
2022-04-05-EMPLICURE-SIGNS-DEVELOPMENT-AGREEMENT-WITH-UPPSAL.pdf Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white tobacco-free nicotine pouches as the first product. Read more at www.emplicure.com
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 